Median Technologies to Participate in Several Investor Conferences in May and June 2025

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:

Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today that the Company will participate in upcoming investor conferences in May and June 2025.

Forum Midcaps Gilbert Dupont
May 13, 2025 - Paris, France

TP ICAP Midcap Annual Conference
May 15-16, 2025 - Paris, France

Portzamparc Mid & Small Caps Conference
June 18-19, 2025 - Paris, France

Please get in touch through the respective conference booking systems, if you would like to request a one-on-one meeting with Median management at these events. Conferences are for institutional investors only.

About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.